DemeRx, founded in 2010 and based in Miami, Florida, is dedicated to developing non-addictive treatments for drug addiction, particularly targeting patients suffering from chronic pain. The company's core mission is to provide innovative, non-addictive drug products that address substance use disorders. DemeRx is currently advancing two molecules through clinical stages, aiming to make significant impacts in billion-dollar markets related to drug and alcohol abuse treatment.
Notable figures associated with DemeRx include its team of experienced researchers and clinicians who drive the company's pioneering efforts. The company has garnered attention from key investors in the healthcare sector, supporting its mission to revolutionize addiction treatment. DemeRx's achievements in advancing its product candidates through clinical trials underscore its potential to significantly impact the field of substance use disorder treatment, offering hope for more effective and safer therapies.
